<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03946592</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ211301</org_study_id>
    <nct_id>NCT03946592</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat</brief_title>
  <acronym>SMF</acronym>
  <official_title>A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase â…¢ Clinical Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of DWJ211 in patient with moderate or severe submental fat
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DWJ211 is a injectable drug for improvement in the appearance of moderate to severe submental
      fat (SMF)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">June 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PA-SMFRS, SA-SMFRS</measure>
    <time_frame>12 week after last treatment</time_frame>
    <description>Proportion of subject who simultaneously have at least a 1 grade, 2grade improvement from baseline on the PA-SMFRS, SA-SMFRS after the last treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Submental Fat</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inject the Drug into submental fat via subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWJ211 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inject the Drug into submental fat via subcutaneous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Inject the Drug into submental fat via subcutaneous</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ211</intervention_name>
    <description>Inject the Drug into submental fat via subcutaneous</description>
    <arm_group_label>DWJ211 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Submental fat grade by the investigator as 2 or 3 using the PA-SMFRS and graded by the
             subject as 2 or 3 using the SA-SMFRS as determined on Visit 1.

          -  Dissatisfaction with the submental area expressed by the subject as a rating of 1~3
             using the SSS as determinded on Visit 1.

          -  Less than 35kg/m2 in body mass index on Visit1.

          -  Subject who will agree with the no treatment for the procedure that may affect to
             reduction or the submental fat.

        Exclusion Criteria:

          -  History of any intervention to treat SMF

          -  History of trauma associated with the chin or neck areas that in the judgement of the
             investigator may affect evaluation of safety or efficacy of treatment.

          -  Evidence of any cause of enlargement in the submental area.

          -  History or current symptoms of dysphagia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MIJUNG SONG</last_name>
    <phone>+82-2-550-8368</phone>
    <email>mjsong257@daewoong.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chung-ang university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

